The cyclin-dependent kinase 5 (CDK5) represents an unusual member of the family of cyclin-dependent kinases, which is activated upon binding to non-cyclin p35 and p39 proteins. The role of CDK5 in the nervous system has been very well established. In addition, there is growing evidence that CDK5 is also active in non-neuronal tissues, where it has been postulated to affect a variety of functions such as the immune response, angiogenesis, myogenesis, melanogenesis and regulation of insulin levels. Moreover, high levels of CDK5 have been observed in different tumour types, and CDK5 was proposed to play various roles in the tumorigenic process. In this review, we discuss these various CDK5 functions in normal physiology and disease, and highlight the therapeutic potential of targeting CDK5.
19 March 2020 in Proceedings of the National Academy of Sciences
Significance: Melanomas are notorious due to their propensity to form lethal metastases. Currently, no treatments are available to stop the metastatic spread. We observed that in malignant melanomas, a protein called the cyclin-dependent kinase 5 (CDK5) is essential for melanoma metastasis. Using mouse and human melanoma cells, we demonstrated that in this tumor type CDK5 promotes the metastatic spread by directly phosphorylating a mesenchymal-type intermediate filament, vimentin. We found that a genetic shutdown of CDK5 in a mouse model of melanoma abrogated metastasis, while chemical inhibition of CDK5 kinase in mice carrying patient-derived tumors impeded the metastatic spread of tumor cells. Our results indicate that inhibition of CDK5 might represent a therapeutic strategy to block the metastatic dissemination of melanoma cells.